Prime Medicine, Inc. (PRME) SEC Filings & Earnings Calls

Going concern uncertainty

“We concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.” · word for word

Dependence on additional financing

“Our ability to continue as a going concern is dependent upon our uncertain ability to obtain additional capital, reduce expenditures and/or execute on our business plan.” · word for word

Pre-revenue stage with no product sales

“To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future.” · word for word

Clinical and regulatory risk; no approved products; cash burn.

“Pre-revenue biotech; cash runway into 2027; clinical data expected in 2027.”

Litigation risk resolved favorably; no ongoing liability.

“Beam's claims denied; no damages awarded.”

Going concern uncertainty

“Substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.” · word for word

No product revenue

“We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future.” · word for word

Dependence on financing

“Our ability to continue as a going concern is dependent upon our uncertain ability to obtain additional capital, reduce expenditures and/or execute on its business plan.” · word for word

Cash burn rate may require future financing before reaching profitability.

“Cash decreased by $42.2M in one quarter; runway only into 2027.”

Clinical and regulatory risk for pipeline programs.

“IND/CTA filings not yet submitted; initial data not expected until 2027.”

Pre-revenue clinical-stage biotech with no approved products

“No product revenue, no approved therapies. Business is entirely dependent on R&D success and partnership milestones.”

Key executive turnover

“CEO and CSO departed in 2025. New CEO and CFO appointed. This creates execution risk.”

Cash runway dependency on partnership and equity financing

“Company has conducted follow-on offerings in Feb 2024 and Aug 2025. Cash position not disclosed in this filing.”

No immediate risk; routine executive transition.

Significant cash burn with no revenue; reliance on pipeline success and funding.

“Net loss $201.1M; cash burn rate high; pre-revenue stage.”

Clinical and regulatory risk for pipeline programs.

“Dependence on IND/CTA filings and clinical trial outcomes; potential for delays or failures.”

Going concern risk

“Because our existing cash, cash equivalents, and investments will not be sufficient to fund our operations, as currently planned, for more than one year beyond the filing date of this Annual Report on Form 10-K, we have determined that there is substantial doubt regarding our ability to continue as a going concern.” · word for word

Clinical development risk

“Clinical drug development involves a lengthy and expensive process, with an uncertain outcome.” · word for word

Technology risk

“Gene editing, including platforms such as Prime Editing, is a relatively new technology that has not been extensively clinically validated for human therapeutic use.” · word for word

No revenue; significant cash burn; reliance on financing.

“Net loss $50.6M; cash $227M; no revenue.”

Cash burn / going concern risk

“Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future” · word for word

Dilution risk from equity raises

“To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interest may be materially diluted” · word for word

Pre-revenue / no product sales

“To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future” · word for word